Rituximab Treatment in a Patient with Active Graves' Orbitopathy and Psoriasis

Creative Commons License

Şimşek T., Yıldırım N., Efe B., Kebapci N.

TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, cilt.47, sa.1, ss.42-46, 2017 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/tjo.26780
  • Dergi Adı: TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.42-46
  • Anahtar Kelimeler: Graves' orbitopathy, rituximab, psoriasis, MONOCLONAL-ANTIBODY RITUXIMAB, B-CELL DEPLETION, TARGETED THERAPY, DISEASE, OPHTHALMOPATHY, PATHOGENESIS, MECHANISMS
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Management of Graves' orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves' orbitopathy. Here we report a case of a 49-year-old woman with Graves' orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart. Although there was improvement in inflammatory signs of the disease, proptosis did not change after the treatment.